Lisdexamfetamine Dimesylate Capsule
Product Images NDC 64850-550

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 64850-550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Elite Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 4 (Figure 4)

A line graph comparing LS Mean (SE) SKAMP Deportment Scores over time post-dose in hours for Lisdexamfetamine Dimesylate versus placebo. The graph features two lines, one solid for Lisdexamfetamine Dimesylate and one dashed for placebo, showing changes in scores from 0 to 13 hours post-dose with error bars representing standard error.*

FDA Label Image

Figure 5 (Figure 5)

A line graph comparing the proportion of subjects with relapse or treatment failure (%) over time (days after randomization) between placebo and Lisdexamfetamine Dimesylate. The placebo group shows a steadily increasing proportion reaching about 70%, while the Lisdexamfetamine Dimesylate group remains below 20% throughout the 50-day period.*

FDA Label Image

Figure 6 (Figure 6)

A line graph comparing LS Mean (SE) PERMP Total Scores over time post-dose (hours) between Lisdexamfetamine Dimesylate and placebo groups. The x-axis shows time points from -0.5 to 14 hours, and the y-axis shows scores ranging approximately from 250 to 330. The Lisdexamfetamine Dimesylate group demonstrates higher scores throughout the time course compared to placebo, with error bars indicating variability.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier curve graph comparing relapse or treatment failure rates over time between Lisdexamfetamine Dimesylate and placebo groups. The x-axis represents time in days after randomization, and the y-axis shows the proportion of subjects with relapse or treatment failure in percentage. The graph has two lines: a solid line for Lisdexamfetamine Dimesylate and a dashed line for placebo.*

FDA Label Image

Figure 8 (Figure 8)

A line graph comparing the proportion of subjects with release (%) over time (days after randomization) between Lisdexamfetamine Dimesylate and placebo groups. The graph includes a legend distinguishing the two groups and a table below indicating the number of subjects at risk at various time points up to 209 days.*

FDA Label Image

Lisdex Caps 10mg (Lisdex Caps 10mg Bottle Label)

Label for Lisdexamfetamine Dimesylate 10 mg capsules by Elite Laboratories, Inc. The label includes storage instructions, controlled substance designation (CII), quantity (100 capsules), and a barcode. It instructs pharmacists to dispense the medication guide and warns to keep medication out of reach of children.*

FDA Label Image

Lisdex Caps 20mg (Lisdex Caps 20mg Bottle Label)

Label for Lisdexamfetamine Dimesylate Capsules 20 mg by Elite Laboratories, Inc. The label includes dosage strength, contains 100 capsules, storage instructions, a controlled substance symbol (CII), and a note to dispense the Medication Guide. The barcode and manufacturer details with issuance date 04/24 are also present.*

FDA Label Image

Lisdex Caps 30mg (Lisdex Caps 30mg Bottle Label)

Label for Lisdexamfetamine Dimesylate Capsules 30 mg by Elite Laboratories, Inc. The label includes storage conditions, NDC 64850-552-01, and states that each capsule contains 30 mg lisdexamfetamine dimesylate. It indicates the package contains 100 capsules and includes pharmacist and dispensing information. The label also features a barcode and manufacture location in Northvale, NJ.*

FDA Label Image

Lisdex Caps 40mg (Lisdex Caps 40mg Bottle Label)

Label of Lisdexamfetamine Dimesylate Capsules 40 mg by Elite Laboratories, Inc. The label includes storage instructions, a warning to keep medication out of children's reach, and packaging details for 100 capsules. It notes the active ingredient lisdexamfetamine dimesylate 40 mg per capsule and the package barcode.*

FDA Label Image

Lisdex Caps 50mg (Lisdex Caps 50mg Bottle Label)

Label for Lisdexamfetamine Dimesylate 50 mg capsules by Elite Laboratories, Inc. The label includes storage instructions, saying to store between 20° to 25°C with permitted excursions, and to dispense in a child-resistant container. The product is prescription only and includes a note to dispense the medication guide to patients. The label states each capsule contains 50 mg lisdexamfetamine dimesylate (equivalent to 28.9 mg lisdexamfetamine). The package contains 100 capsules.*

FDA Label Image

Lisdex Caps 60mg (Lisdex Caps 60mg Bottle Label)

Lisdexamfetamine Dimesylate Capsules 60 mg label from Elite Laboratories, Inc. The label includes storage instructions, a note for pharmacists to dispense medication guide, the NDC number 64850-555-01, and a barcode. The package contains 100 capsules and is labeled for oral use with child-resistant packaging.*

FDA Label Image

Lisdex Caps 70mg (Lisdex Caps 70mg Bottle Label)

Lisdexamfetamine Dimesylate 70 mg capsules label by Elite Laboratories, Inc. The label includes storage instructions, prescription-only status, quantity of 100 capsules, active ingredient content, and manufacturer information. It also highlights child-resistant packaging and dosage guidance reference.*

FDA Label Image

Chemical Structure (Vyvanse 01)

Chemical structure diagram of lisdexamfetamine dimesylate showing molecular components including amine and benzene groups alongside two methanesulfonic acid residues.*

FDA Label Image

Figure 1 (Vyvanse 02)

A fold change graph illustrating the pharmacokinetic parameters Cmax and AUC for lisdexamfetamine dimesylate in special populations, including gender (male/female), age groups (65-74 and 75+ years), and varying degrees of renal impairment (mild, moderate, severe, end stage renal disease). The x-axis shows change relative to reference from 0.0 to 2.5 with 90% confidence intervals displayed as error bars for each parameter and population group.*

FDA Label Image

Figure 2 (Vyvanse 03)

A pharmacokinetic graph showing fold change and 90% confidence intervals of Cmax and AUC values for three drugs: Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference (0.0 to 2.0), with data points plotted around 1.0 to illustrate drug interaction effects.*

FDA Label Image

Figure 3 (Vyvanse 04)

A fold change plot showing pharmacokinetic parameters Cmax and AUC with 90% confidence intervals for various interacting drugs including Guanfacine, Venlafaxine, CYP1A2 substrates (Caffeine), CYP2D6 substrates (Dextromethorphan), CYP2C19 substrates (Omeprazole), and CYP3A substrates (Midazolam). The x-axis represents change relative to reference from 0.0 to 2.0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.